Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
51.1M
-
Number of holders
-
163
-
Total 13F shares, excl. options
-
41.7M
-
Shares change
-
-835
-
Total reported value, excl. options
-
$298M
-
Value change
-
-$1.5M
-
Put/Call ratio
-
1.64
-
Number of buys
-
83
-
Number of sells
-
-95
-
Price
-
$7.15
Significant Holders of REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX) as of Q1 2025
217 filings reported holding RGNX - REGENXBIO Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX) has 163 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41.7M shares
of 51.1M outstanding shares and own 81.48% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (5.45M shares), Redmile Group, LLC (4.79M shares), JPMORGAN CHASE & CO (4.36M shares), VANGUARD GROUP INC (3.47M shares), MORGAN STANLEY (2.07M shares), Balyasny Asset Management L.P. (1.4M shares), DIMENSIONAL FUND ADVISORS LP (1.15M shares), GEODE CAPITAL MANAGEMENT, LLC (1.11M shares), STATE STREET CORP (1.07M shares), and CITADEL ADVISORS LLC (1.03M shares).
This table shows the top 163 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.